[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579956":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":28,"responsibleParty":44,"collaborators":20,"id":46,"slug":20,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":20,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":20,"overallStatus":31,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SBRT delivered with CBCT-guided online adaptive RT","EXPERIMENTAL","Patients will undergo CT guided online adaptive SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25Gy in 5 fractions ENI to PA nodes (+\u002F- pelvic nodes).",[13],"Radiation: Adaptive radiotherapy using SBRT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Adaptive radiotherapy using SBRT","Adaptive External beam radiotherapy using SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25 Gy in 5 fractions ENI to PA nodes (+ common iliac nodes)",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Andrew McPartlin, MD","CONTACT","416-946-4501","4855","andrew.mcpartlin@uhn.ca",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Princess Margaret Cancer Centre","RECRUITING","Toronto","Ontario","M5G 2M9","Canada",{"type":37,"coordinates":38},"Point",[39,40],-79.39864,43.70643,{"lat":40,"lon":39},[43],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100579956",false,"NCT06831032","Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response","A Phase I, Prospective, Single-Arm Feasibility Study: Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response (EASY)","EASY","Inclusion Criteria:\n\n1. Histologically confirmed prostate adenocarcinoma.\n2. Oligorecurrent para-aortic +\u002F- common iliac nodal disease planned for SBRT.\n3. ≤10 involved para-aortic (defined as between L1\u002FL2 interface and L4\u002FL5 interface) +\u002F- common iliac LN on PSMA PET imaging.\n4. ECOG performance status 0-2.\n\nExclusion Criteria:\n\n1. Prior radiotherapy to the nodal echelon (PA +\u002F- common iliac).\n2. Active secondary malignancy, except for adequately treated non-melanoma skin cancer.\n3. Presence of significant comorbidities or medical conditions that may compromise the ability to undergo radiotherapy or participate in the study.\n4. Contraindication to radiation.","MALE","18 Years",{"count":56,"type":57},26,"ESTIMATED","INTERVENTIONAL",[60],"NA","This prospective, single-arm feasibility study will include patients with prostate cancer that have controlled local disease diagnosed with oligorecurrent para-aortic nodal disease and\u002For common iliac nodal disease detected by PSMA PET or conventional CT\u002FMRI imaging, and these patients will undergo CT-guided online adaptive SBRT to the tumor and elective SBRT to adjacent at-risk nodal regions.",[63,64,65,66,67],"Prostate Adenocarcinoma","Iliac Nodal Disease","Para-aortic Lymph Node Metastasis","Para-aortic Nodal Disease","Oligorecurrence","2026-03-18",{"date":70,"type":71},"2026-03-23","ACTUAL",{"date":73,"type":57},"2026-07-07",{"date":75,"type":57},"2029-07-07",{"name":5,"class":6},1]